Table 3.
Multivariable linear regression for change in modified mini screen score from baseline to week 4, week 12, and week 24 among participants with available estimated dolutegravir AUC0-24 concentrations
| Multivariable associations Week 4 (n = 461) |
Multivariable associations Week 12 (n = 461) |
Multivariable associations Week 24 (n = 461) |
||||
|---|---|---|---|---|---|---|
| Coefficient (95% CI) | P value | Coefficient (95% CI) | P valuea | Coefficient (95% CI) | P valuea | |
| Age (per 10 years increase) | −0.214 (−0.528 to 0.100) | 0.181 | −0.155 (−0.427 to 0.118) | 0.265 | −0.119 (−0.342 to 0.104) | 0.296 |
| Sex | ||||||
| Female | Referent group | |||||
| Male | 0.111 (−0.263 to 0.486) | 0.559 | 0.167 (−0.173 to 0.507) | 0.336 | 0.109 (−0.188 to 0.406) | 0.472 |
| Baseline CD4 count (per 50 cells/mm3 increase) | −0.045 (−0.104 to 0.015) | 0.141 | −0.019 (−0.076 to 0.039) | 0.521 | −0.027 (−0.075 to 0.020) | 0.258 |
| Baseline HIV-1 RNA (per 1 log10 increase) | −0.140 (−0.394 to 0.114) | 0.280 | −0.133 (−0.394 to 0.127) | 0.315 | −0.115 (−0.324 to 0.094) | 0.281 |
| Arm | ||||||
| TAF | Referent group | |||||
| TDF | −0.161 (−0.537 to 0.216) | 0.402 | −0.009 (−0.365 to 0.348) | 0.962 | −0.107 (−0.409 to 0.194) | 0.486 |
| DTG AUC0-24 (mg·h/L) (per 1 log10 increase) | −0.826 (−2.037 to 0.385) | 0.181 | −1.278 (−2.250 to −0.306) | 0.010 | −1.145 (−1.953 to −0.338) | 0.006 |
TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; DTG, dolutegravir; AUC0-24, area under the concentration-time curve; PK, pharmacokinetics.
a
P values <0.05 are shown in bold.